Doctors track new HAE Treatment's Real-World performance

This study observed 155 people in Japan who were starting treatment with Lanadelumab for hereditary angioedema (HAE), a condition that causes severe swelling attacks. The main goal was to monitor for side effects and see if the treatment helped reduce the number of swelling episodes over 12 months of regular use. It was a 'real-world' survey, meaning patients received the drug as part of their normal clinic care while researchers collected data on safety and quality of life.